FDA WARNING_LETTER - LifeSilver - October 31, 2014
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
In October 2014, the FDA and FTC reviewed LifeSilver's website (lifesilver.com) and Facebook page, identifying violations related to their products: "ASAP Solution," "Patis 30 Fortified Silver Solution," "ASAP Ultimate Skin & Body Care Gel," "Combo Wellness Pack," and "Combo Gel Pack."
The agencies determined that therapeutic claims on the website and Facebook, such as "EBOLA AND NANO-SILVER VIRAL IMMUNIZATION" and claims about preventing/treating viral infections (including Ebola), cause these products to be unapproved new drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)]. These products are not generally recognized as safe and effective for their claimed uses, making them "new drugs" under section 201(p) of the Act [21 U.S.C. § 321(p)], requiring prior FDA approval.
Furthermore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] because they are offered for conditions not amenable to self-diagnosis and treatment, meaning adequate directions for layperson use cannot be provided. The letter also notes that while
ID · 966b2619-7f39-457b-a49b-7e6159784c4d
Full citation text and observation details available on the Dashboard.